Many laboratories in the UK would not be able to exclude D. fragilis and B. hominis, therefore it is possible that some patients infected with these parasites could be misdiagnosed as having IBS. Anecdotal evidence suggests that many patients infected with these parasites are indeed being misdiagnosed as having IBS.D. fraglis and B. hominis: neglected human protozoa. J. J. Windsor. The Biomedical Scientist. July 2007. Pages 524-27.
The clinical consequences of B. hominis infection are mainly diarrhea or abdominal pain with nonspecific gastrointestinal symptoms such as nausea, anorexia, vomiting, weight loss, lassitude, dizziness, and flatulence.Irritable Bowel Syndrome: In search of an etiology: role of B. hominis. Javed Yakoob et al. Am. J. Trop. Med. Hyg., 70(4), 2004, pp. 383-385
Most recent literature accepts that D. fragilis is an important enteric pathogen with an estimated incidence of symptomatic infection of between 4 and 91%. Symptoms include abdominal pain, bloating, and diarrhea.Peek et al, 2004, American Society for Microbiology
"The clinical consequences of B. hominis infection are mainly diarrhea and abdominal pain as well as nonspecific gastrointestinal symptoms such as nausea, anorexia, vomiting, weight loss, lassitude, dizziness, and flatulence. Case reports and series have suggested a pathogenic role of B. hominis in causing intestinal inflammation. Also some studies have suggested that inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are associated with B. hominis infection. The investigators indicate that the stools of all patients presenting with IBD or IBS should be examined, and culture methods for B. hominis carried out. Invasion and mucosal inflammation of the intestine with B. hominis have been observed in studies of gnotobiotic guinea pigs."Blastocystis hominis and bowel diseases. Turkiye Parazitol Derg. 2006;30(1):72-76
After several years of almost constant and distressing symptoms I finally found a doctor who was willing to consider the D.fragilis research in its entirety, instead of the usual approach - cherry-picking the scientific evidence to suit prevailing medical dogma that D.fragilis is harmless. Read here how I doctor-shopped my way around Sydney in my search to find relief from the chronic, disabling symptoms triggered by Blasto. and D.fragilis.
B.hominis and D.fragilis can trigger tummy aches and altered stool to full blown chronic illness. Read why this hidden epidemic can drive some chronically ill people to consider suicide as a way to escape the symptoms.
Drug treatments: Flagyl is the most widely prescribed drug to treat Blasto. and D.fragilis, despite little to recommend it. The experience of a Sydney GI clinic proves that the triple therapy is the most effective treatment currently available to treat Blasto.
D.fragilis is treated slightly differently.
If medicine separated facts from its own beliefs then more patients would end up like the ones I've documented here.
The medical approach to diagnosis and treatment may exert a higher price than years of unnecessary suffering. More about the under-acknowledged and under-recognised consequences resulting from long term infections in:
A 1983 study in the American Journal of Gastroenterology warned that a single single stool specimen examination will miss many pathogenic protozoan infections in symptomatic persons. Over three decades later this test is still the diagnostic standard in many countries.
Essential facts you should know, gleaned from the scientific literature about stool testing
Why do IBS think tanks insist that stool testing is unnecessary in patients with IBS symtpoms, when studies show that at least half of patients with IBS harbour Blasto. and D.fragilis? Read more here.
For almost 17 years I've been documenting what happens to people with D.fragilis and Blasto. It's a damning picture of 21st Century medicine.
Entamoeba histolytica is a recognised pathogen, but because such little attention is paid to gut parasites in western medicine, patients with E.h. encounter many of the same hurdles to recovery as patients with D.fragilis and Blasto.